Thanks to the passage of Proposition 14, Texas now boasts the country’s largest state-funded initiative dedicated to dementia research and prevention. Photo via Unsplash.

Texas voters on Nov. 4 overwhelmingly approved a ballot measure that provides $3 billion in state funding over a 10-year span for the newly established Dementia Prevention and Research Institute of Texas (DPRIT).

Thanks to the passage of Proposition 14, Texas now boasts the country’s largest state-funded initiative dedicated to dementia research and prevention, according to the Alzheimer’s Association. Up to $300 million in grants will be awarded during the 10-year funding period.

“This is a transformative moment for Texas and for the fight against Alzheimer’s and all other dementia,” said Joanne Pike, president and CEO of the Alzheimer’s Association. “Texans have chosen to invest in hope, innovation, and solutions for the millions of families affected by these devastating diseases. With the passage of Proposition 14, Texas is now poised to lead the nation in dementia research and prevention.”

The association says DPRIT will drive scientific breakthroughs, attract top-notch dementia researchers to Texas, and generate thousands of jobs statewide.

An estimated 460,000 Texans are living with dementia, the association says, and more than one million caregivers support them.

DPRIT is modeled after the Cancer Prevention and Research Institute of Texas (CPRIT). Since 2008, the state agency has awarded nearly $4 billion in grants to research organizations for cancer-related academic research, prevention programs, and product development.

An analysis by the McKinsey Health Institute found that investing in brain health initiatives like DPRIT could boost Texas’ GDP by $260 billion. Much of that GDP bump could benefit the Houston area, which is home to dementia-focused organizations such as UTHealth Houston Neurosciences, Baylor College of Medicine’s Center for Alzheimer’s and Neurodegenerative Diseases, the University of Texas Medical Branch at Galveston’s Collaborative Alzheimer’s Disease and Memory Disorders Program, and the Houston Methodist Research Institute’s John M. O’Quinn Foundation Neurodegenerative Disorders Laboratory.

The Greater Houston Partnership says DPRIT holds the potential “to elevate Texas — particularly Houston — as a hub for brain health research.”

State Sen. Joan Huffman, a Houston Republican, is one of DPRIT’s champions. She sponsored legislation this year to create the institute and ask Texas voters to approve the $3 billion in funding.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said in May. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our health care community.”

Four major metros in Texas have teamed up to advocate for the LGBT community. VlatkoRadovic/Getty Images

Texas LGBT chambers of commerce form coalition to advocate for the community

One for all

The LGBT chambers of commerce in the Houston, Austin, San Antonio, and Dallas areas have combined forces to create the Texas LGBT Chambers of Commerce with the mission of advancing and advocating for LGBT business leaders and allies within the state.

The four founding entities of the coalition represent over 1,000 LGBT-owned and LGBT-allied business interests, according to a release.

"The Greater Houston LGBT Chamber of Commerce is proud to stand with our sister LGBT chambers across the state to bring the power of our collective voices to advocate on behalf of the LGBT business community," says Tammi Wallace, co-founder and chair of the Greater Houston LGBT Chamber of Commerce, in the release. "Representing hundreds of LGBT-owned and LGBT-allied businesses — and growing — our work together is even more important as we unify to represent our members through advocacy and other collaborative opportunities."

The coalition will host an advocacy day at the Texas Capital on Feb. 20 with the goal being to introduce lawmakers to the coalition and address business issues regarding the LGBT community, according to the release

"There is power in numbers," says Clint Thomson, chair of the North Texas GLBT Chamber of Commerce, in the release. "This new alliance will enable us to work collectively on behalf of all LGBT-owned and LGBT-allied businesses throughout the Lone Star State."

The group effort is a response to the anti-transgender "bathroom bill" that was introduced to lawmakers in the 2017 Texas Legislative Session. While the bill didn't pass, a study showed that it would have had a negative economic impact of $8.5 billion and a loss of 185,000 jobs.

"The Texas LGBT Chambers of Commerce intends to prevent any and all anti-LGBT, economy-damaging measures from becoming law in Texas at the state and local levels," says Chase Kincannon, chair of the Austin LGBT Chamber of Commerce, in the release.

As of January 29, no legislation regarding the LGBT community was recognized as active within the 86th Texas Legislative Session.

TxDOT has a new task force focused on keeping Texans informed on self-driving vehicles that are getting road ready. Getty Images

Texas forms task force geared at autonomous vehicle development

Road to unmanned driving

Self-driving cars are en route to Texas, and the state government wants to ensure Texas is ready for the ride. The Texas Department of Transportation announced the creation of a Connected and Autonomous Vehicle Task Force on Jan. 24.

The CAV Task Force will focus on being a comprehensive resource for information on all Texas CAV projects, investments, and initiatives, the press release says. The organization will also host events surrounding CAV progress and education around the topic.

"With our world-class universities, top-notch workforce and startup culture, Texas is a national leader in the development of new technologies," says Gov. Greg Abbott in the release. "As transportation technology advances, the CAV Task Force will ensure that the Lone Star State remains at the forefront of innovation."

TxDOT's interest, the release reports, is in hopes that the self-driving technology will minimize accidents and maximize safety, as well as expand opportunities for residents, especially within the elderly and disabled populations who currently don't have reliable transportation to their errands and appointments.

In 2017, in the 85th Texas Legislative Session, Abbot signed Senate Bill 2205 into law. The legislation identifies key requirements for CAVs, such as insurance and adhering to traffic laws, like normal vehicles, as well as requiring video recording devices in the car, the Texas Tribune reported. However, it's worth nothing that self-driving vehicles were already being experimented with in Austin by the likes of Google, the Tribune notes.

"Our goal is to further build on the momentum already established with the Texas Technology Task Force and the Texas Innovation Alliance, and work with interested parties on the latest and greatest in CAV projects and enhancements," says TxDOT Executive Director James Bass. "We look forward to furthering these important efforts as connected and autonomous vehicles become reality."

TxDOT is also focusing on rail planning, as the Houston-Dallas high-speed rail chugs along. Earlier this month, the state asked for Texans' feedback on the projects.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”